GENE ONLINE|News &
Opinion
Blog

2022-01-17| Partner

Digital Health Programme to Connect British and Taiwanese Leaders

by Joy Lin
Share To

Taiwan’s digital health industry, powered by its state-of-the-art ICT sector, presents an exciting opportunity for overseas investment and collaboration. The British Office Taipei, in collaboration with GeneOnline, is arranging an exclusive webinar only for UK businesses and matchmaking events for both UK and Taiwan businesses in ICT, VC, medical AloT, Medtech, digital health and research to identify prospective partners. 

 

The Key Strengths of Taiwan’s Digital Health

 

Taiwan is more known for its semiconductors, less so for its digital health industry. Both are, in fact, two sides of the same coin, powered by Taiwan’s state-of-the-art information and communications technology (ICT). 

The island is constantly exploring ways to incorporate ICT into the healthcare sector, and reimagining how healthcare providers can offer services. 

As a result, digital health has taken off, spawning mobile apps that could test for COVID-19, artificial applications that could aid physicians with detecting diseases such as cancer, and more.

Taiwan’s advancements in digital health have attracted international attention. The UK and Taiwan could share complementary strengths in digital health and medical AloT, have similar public health structures and have geographical proximity to the larger APAC region. 

An exclusive webinar and B2B Matchmaking for the UK businesses and academia will offer them an opportunity to connect with Taiwanese companies for future collaboration. 

 

Understanding the Forces Driving Taiwan’s Healthcare 

 

The 2022 UK-Taiwan Digital Health Webinar held on February 10 will offer valuable insights about Taiwan’s market and regulatory landscape, which, along with matchmaking events, explore areas of joint interest, research, and links to commercial partners in Taiwan. It will cover three main topics: 

  • Taiwan’s Healthcare System 

  • The Digital Health Market Landscape

  • An Overview of the Regulatory Environment

 

The 2022 UK-Taiwan Digital Health Programme Webinar Agenda

 

“Introduction of Taiwan’s Healthcare System” will be presented by Marc Min-Huei Hsu, Dean of the Office of Data Science at Taipei Medical University and former head of the Department of Information Management at the Ministry of Health and Welfare. 

Besides detailing the healthcare system and state of patient care in Taiwan, Hsu will also outline the uptake of digital innovations with healthcare providers such as hospitals. 

Next, Brian Chong, Vice President of Wistron Medical Technology, will present on the topic “Introducing the Digital Health Market in Taiwan”.

Chong will give an overview of Taiwan’s digital health market, covering key strengths and emphasizing unmet market needs and opportunities.  

The last topic “An Overview of the Regulatory Environment in Taiwan” will be discussed by Jarret Su, Co-Head of Healthcare & Life Science, KPMG in Taiwan.

Su will focus on the regulatory aspects of digital health in Taiwan, and highlight the opportunities and challenges in entering the industry. 

Following the webinar, the B2B Matchmaking held on March 7- 11 allows selected organisations in ICT, VC, Medical AIoT, MedTech, digital health, and research to identify prospective partners and create sustainable collaboration with the 1-1 partnering platform in real-time.

 

Registering for Webinar and Matchmaking Today

 

The webinar: February 10, from 8:30-10:00 (GMT)

The B2B Matchmaking: March 7-11 

The 2022 UK-Taiwan Digital Health Programme

For more information and to register, please click here.

For enquiries, please contact Sarah Wang (sarah.wang@fcdo.gov.uk) or Guinnevere Sung (guinnevere.sung@geneonlineasia.com).

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
R&D
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
AI-Driven Breakthroughs in Drug Discovery and Treatment Optimization
2024-04-02
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
Scroll to Top